|
|
|
|
|
Session 88
Poster Presentations Adverse Drug Reactions Associated with Antiretroviral Drugs Session Day and Time: Tuesday 1:30 - 3:30 pm Room: Hall B |
Background: Insomnia is frequently
found in patients (pts) receiving efavirenz (EFV). It generally resolves within
the first month on treatment, although eventually may lead to EFV
discontinuation. Information on the sleep pattern alterations induced by EFV
and their potential association with EFV plasma levels is scarce.
Methods: A
total of 18 HIV+ subjects receiving EFV for at least 1 month, and a
control group of 13 healthy volunteers were recruited in the study. Insomnia
was assessed through sleep diaries and the Pittsburgh Sleep Quality Index
(PSQI) and psychiatric screening ruled out other mental co-morbidities. Ambulatory
(Holter) EEG monitoring was used to record sleep architecture in HIV+
and healthy controls. EFV plasma trough levels were measured in HIV+
pts.
Results: Sleep diaries and the PSQI
identified insomnia in 13 subjects receiving EFV, while normal results were
obtained in the remaining 5 HIV+ pts on EFV and in all 13 healthy
controls. In comparison with subjects without sleep disturbances, pts with
EFV-related insomnia showed lower sleep efficacy (81 ±15%
vs 96 ±7%, p < 0.01), longer total time awake (20 ±15%
vs 4 ±0.2%, p < 0.01), shorter REM (14 ±6%
vs 22 ±3%, p < 0.01), and shorter NREM stage 2 (43 ±6%
vs 56 ±7%, p < 0.01) in the ambulatory
EEG monitoring. Conversely, HIV+ pts on EFV, irrespectively of
suffering insomnia, showed longer sleep latencies than healthy controls (32 ±28
mins vs 11 ±3 mins, p < 0.01), and shorter NREM stage 3
(6 ±4% vs 9 ±2%, p < 0.01) and NREM
stage 4 (4 ±4% vs 13 ±2%, p < 0.01). No
differences were observed in the total sleep night-time among the 3 groups.
There was no correlation between EFV trough levels and the development of sleep
abnormalities.
Conclusions: HIV+ pts on EFV
complaining insomnia often show severe alterations in sleep architecture, as
demonstrated in ambulatory EEG monitoring. In addition to overall lower sleep
efficacy, characteristic reductions in REM and NREM stages 3 and 4 (deep sleep)
in subjects on EFV, complaining or not insomnia, could be associated with
cognitive dysfunction and fatigue, respectively.